Global Female Infertility Diagnosis and Treatment Market Research and Analysis, 2015-2022
MARKET INSIGHTS
The global female infertility market is estimated to grow with the CAGR of 4.7% during the period 2017-2022. The major factors that are augmenting the growth of the female infertility market are changing life style and increasing IVF market. Furthermore, increasing female geriatric population, rising trend of surrogacy, growing infertility rate among female, new technologies to avoid multiple embryo implants are the also estimated to be the major factors that are contributing significantly towards the growth of the market.
Increasing female geriatric population is the key factors driving the growth of the female infertility market across the globe.in the year 2015, overall female population in the world was estimated to be about 3.6 billion, out of which 342 million female across the globe was estimated to be aged 65 years or older. Female geriatric population accounts for 4.8% of the overall world population. The female geriatric population are further estimated to reach 553 million by the year 2030 and 850 million by the year 2050. Infertility is the major problem in the female aging more than 35.therefore increasing female geriatric population is anticipated to fuel the growth of the market during the forecast period.
However, there are certain factors that are affecting the growth of the market. High cost infertility treatment, low accuracy rate of the treatment and social stigma related to the infertility treatment are the major factors constraints that are hindering the growth of the global female infertility market across the globe.
GEOGRAPHY INSIGHTS
Global female infertility market is analyzed on the basis of the geographical regions that are contributing significantly towards the growth of the market. On the basis of the geography, market is bifurcated into North America, Europe, Asia Pacific and Rest of the World. North America is estimated to be the leading region in the global infertility market. Increasing female geriatric population in the region, and changing lifestyle is one of the major factors driving the growth of the market in the region. In US about 40 million population is age 65 and older, it is further estimated to reach 72 million by the year 2030 and more than 85 million by the year 2050. Increasing IVF market is also one of the major factor driving the growth of the market in the region. Asia Pacific is estimated to be the fastest growing region during the forecast period 2017-2022. Increasing medical tourism in Asia and increasing geriatric population in China and India are estimated to be the major factors driving the growth of the market.
COMPETITIVE INSIGHTS
Key players of the female infertility market are Bayer Ag, Bristol-Myers Squibb Co, Church & Dwight Company Inc., Cook Medical Inc., Coopersurgical Inc, Eli Lilly & Co., Emd Serono Inc, Endo Pharmaceuticals Inc, Ferring Pharmaceuticals, Genea, GlaxoSmithKline Plc, Halotech DNA, Irvine Scientific, Janssen Pharmaceutical, Merck Serono, Novartis International Ag, Origio, Ovascience, Pfizer Inc, and Princeton. In order to survive in the market these players adopt different marketing strategies such as merger, acquisitions, product launch, and geographical expansion so on. For Example: In 2016, Bayer AG acquired Monsanto a US based company in a $66 billion deal.
MARKET SEGMENTATION
1. GLOBAL FEMALE INFERTILITY MARKET BY DIAGNOSIS
1.1. OVULATION TESTING MARKET
1.2. HYSTEROSALPINGOGRAPHY MARKET
1.3. HYSTEROSCOPY MARKET
1.4. IMAGING TESTING MARKET
1.5. OVARIAN RESERVE TESTING MARKET
1.6. HORMONAL LEVEL TESTING MARKET
1.7. GENETIC TESTING MARKET
1.8. OTHERS
2. GLOBAL FEMALE INFERTILITY MARKET BY TREATMENT
2.1. DRUGS AND MEDICINE MARKET
2.2. SURGICAL MARKET
2.3. INTRAUTERINE INSEMINATION (IUI) MARKET
2.4. ASSISTED REPRODUCTIVE TECHNOLOGY (ART) MARKET
2.5. Others
OMR REPORT COVERS:
The global female infertility market is estimated to grow with the CAGR of 4.7% during the period 2017-2022. The major factors that are augmenting the growth of the female infertility market are changing life style and increasing IVF market. Furthermore, increasing female geriatric population, rising trend of surrogacy, growing infertility rate among female, new technologies to avoid multiple embryo implants are the also estimated to be the major factors that are contributing significantly towards the growth of the market.
Increasing female geriatric population is the key factors driving the growth of the female infertility market across the globe.in the year 2015, overall female population in the world was estimated to be about 3.6 billion, out of which 342 million female across the globe was estimated to be aged 65 years or older. Female geriatric population accounts for 4.8% of the overall world population. The female geriatric population are further estimated to reach 553 million by the year 2030 and 850 million by the year 2050. Infertility is the major problem in the female aging more than 35.therefore increasing female geriatric population is anticipated to fuel the growth of the market during the forecast period.
However, there are certain factors that are affecting the growth of the market. High cost infertility treatment, low accuracy rate of the treatment and social stigma related to the infertility treatment are the major factors constraints that are hindering the growth of the global female infertility market across the globe.
GEOGRAPHY INSIGHTS
Global female infertility market is analyzed on the basis of the geographical regions that are contributing significantly towards the growth of the market. On the basis of the geography, market is bifurcated into North America, Europe, Asia Pacific and Rest of the World. North America is estimated to be the leading region in the global infertility market. Increasing female geriatric population in the region, and changing lifestyle is one of the major factors driving the growth of the market in the region. In US about 40 million population is age 65 and older, it is further estimated to reach 72 million by the year 2030 and more than 85 million by the year 2050. Increasing IVF market is also one of the major factor driving the growth of the market in the region. Asia Pacific is estimated to be the fastest growing region during the forecast period 2017-2022. Increasing medical tourism in Asia and increasing geriatric population in China and India are estimated to be the major factors driving the growth of the market.
COMPETITIVE INSIGHTS
Key players of the female infertility market are Bayer Ag, Bristol-Myers Squibb Co, Church & Dwight Company Inc., Cook Medical Inc., Coopersurgical Inc, Eli Lilly & Co., Emd Serono Inc, Endo Pharmaceuticals Inc, Ferring Pharmaceuticals, Genea, GlaxoSmithKline Plc, Halotech DNA, Irvine Scientific, Janssen Pharmaceutical, Merck Serono, Novartis International Ag, Origio, Ovascience, Pfizer Inc, and Princeton. In order to survive in the market these players adopt different marketing strategies such as merger, acquisitions, product launch, and geographical expansion so on. For Example: In 2016, Bayer AG acquired Monsanto a US based company in a $66 billion deal.
MARKET SEGMENTATION
1. GLOBAL FEMALE INFERTILITY MARKET BY DIAGNOSIS
1.1. OVULATION TESTING MARKET
1.2. HYSTEROSALPINGOGRAPHY MARKET
1.3. HYSTEROSCOPY MARKET
1.4. IMAGING TESTING MARKET
1.5. OVARIAN RESERVE TESTING MARKET
1.6. HORMONAL LEVEL TESTING MARKET
1.7. GENETIC TESTING MARKET
1.8. OTHERS
2. GLOBAL FEMALE INFERTILITY MARKET BY TREATMENT
2.1. DRUGS AND MEDICINE MARKET
2.2. SURGICAL MARKET
2.3. INTRAUTERINE INSEMINATION (IUI) MARKET
2.4. ASSISTED REPRODUCTIVE TECHNOLOGY (ART) MARKET
2.5. Others
OMR REPORT COVERS:
- Comprehensive research methodology of Global Female Infertility Market
- This report also includes detailed and extensive market overview with Analyst insights & key market trends.
- Exhaustive analysis of macro and micro factors influencing the market guided by key recommendations.
- Analysis of regional regulations and other government policies impacting the Global Female Infertility Market
- Insights about market determinants which are stimulating the Global Female Infertility Market
- Detailed and extensive market segments with regional distribution of forecasted revenues.
- Extensive profiles and recent developments of market players.
1. REPORT SUMMARY
1.1. RESEARCH METHODS AND TOOLS
1.2. MARKET BREAKDOWN
1.2.1. BY SEGMENTS
1.2.2. BY GEOGRAPHY
1.2.3. BY STAKEHOLDERS
2. MARKET OVERVIEW AND INSIGHTS
2.1. DEFINITION
2.2. ANALYST INSIGHTS & CURRENT MARKET TRENDS
2.2.1. KEY FINDINGS
2.2.2. RECOMMENDATION
2.2.3. CONCLUSION
2.3. REGULATIONS
2.3.1. UNITED STATES
2.3.2. EUROPEAN UNION
2.3.3. CHINA
2.3.4. INDIA
2.3.5. REST OF THE WORLD
3. MARKET DETERMINANT
3.1. MOTIVATORS
3.1.1. CHANGING LIFE STYLE
3.1.2. RISING TREND OF SURROGACY
3.1.3. INCREASING FEMALE GERIATRIC POPULATION
3.1.4. NEW TECHNOLOGIES TO AVOID MULTIPLE EMBRYO IMPLANTS
3.1.5. INCREASING IVF TREAMENT MARKET
3.1.6. GROWING INFERTILITY RATE AMONG FEMALE
3.2. RESTRAINTS
3.2.1. HIGH COST OF TREATMENT
3.2.2. INCREASING INCIDENCES OF TREATMENT FAILURES
3.2.3. SOCIAL STIGMA RELATED TO INFERTILITY TREATMENT
3.3. OPPORTUNITIES
3.3.1. INCREASING MEDICAL TOURISM
3.3.2. INCREASING AWARENESS AMONG PEOPLE
4. MARKET SEGMENTATION
4.1. GLOBAL FEMALE INFERTILITY MARKET BY DIAGNOSIS
4.1.1. OVULATION TESTING MARKET
4.1.2. HYSTEROSALPINGOGRAPHY MARKET
4.1.3. HYSTEROSCOPY MARKET
4.1.4. IMAGING TESTING MARKET
4.1.5. OVARIAN RESERVE TESTING MARKET
4.1.6. HORMONAL LEVEL TESTING MARKET
4.1.7. GENETIC TESTING MARKET
4.1.8. OTHERS
4.2. GLOBAL FEMALE INFERTILITY MARKET BY TREATMENT
4.2.1. DRUGS AND MEDICINE MARKET
4.2.2. SURGICAL MARKET
4.2.3. INTRAUTERINE INSEMINATION (IUI) MARKET
4.2.4. ASSISTED REPRODUCTIVE TECHNOLOGY (ART) MARKET
4.2.5. Others
5. COMPETITIVE LANDSCAPE
5.1. KEY STRATEGIES ANALYSIS
5.2. KEY COMPANY ANALYSIS
6. REGIONAL ANALYSIS
6.1. NORTH AMERICA
6.1.1. UNITED STATES
6.1.2. CANADA
6.1.3. REST OF NORTH AMERICA
6.2. EUROPE
6.2.1. UNITED KINGDOM
6.2.2. FRANCE
6.2.3. GERMANY
6.2.4. ITALY
6.2.5. SPAIN
6.2.6. REST OF EUROPE
6.3. ASIA PACIFIC
6.3.1. INDIA
6.3.2. CHINA
6.3.3. JAPAN
6.4. REST OF THE WORLD
7. COMPANY PROFILES
7.1. BAYER AG
7.1.1. Introduction
7.1.2. BAYER AG PRODUCT PORTFOLIO
7.1.3. BAYER AG RECENT ACTIVITIES
7.2. BRISTOL-MYERS SQUIBB CO.
7.2.1. INTRODUCTION
7.2.2. BRISTOL-MYERS SQUIBB CO. PRODUCT PORTFOLIO
7.2.3. BRISTOL-MYERS SQUIBB CO. RECENT ACTIVITIES
7.3. CHURCH & DWIGHT COMPANY INC.
7.3.1. INTRODUCTION
7.3.2. CHURCH & DWIGHT COMPANY INC. PRODUCT PORTFOLIO
7.3.3. CHURCH & DWIGHT COMPANY INC. RECENT ACTIVITIES
7.4. COOK MEDICAL, INC.
7.4.1. INTRODUCTION
7.4.2. COOK MEDICAL, INC. PRODUCT PORTFOLIO
7.4.3. COOK MEDICAL, INC. RECENT ACTIVITIES
7.5. COOPERSURGICAL INC.
7.5.1. INTRODUCTION
7.5.2. COOPERSURGICAL INC. PRODUCT PORTFOLIO
7.5.3. COOPERSURGICAL INC. RECENT ACTIVITIES
7.6. ELI LILLY & CO.
7.6.1. INTRODUCTION
7.6.2. ELI LILLY & CO. PRODUCT PORTFOLIO
7.6.3. ELI LILLY & CO. RECENT ACTIVITIES
7.7. EMD SERONO, INC
7.7.1. INTRODUCTION
7.7.2. EMD SERONO, INC PRODUCT PORTFOLIO
7.7.3. EMD SERONO, INC RECENT ACTIVITIES
7.8. ENDO PHARMACEUTICALS INC.
7.8.1. INTRODUCTION
7.8.2. ENDO PHARMACEUTICALS INC. PRODUCT PORTFOLIO
7.8.3. ENDO PHARMACEUTICALS INC. RECENT ACTIVITIES
7.9. FERRING PHARMACEUTICALS
7.9.1. INTRODUCTION
7.9.2. FERRING PHARMACEUTICALS PRODUCT PORTFOLIO
7.9.3. FERRING PHARMACEUTICALS RECENT ACTIVITIES
7.10. GENEA
7.10.1. INTRODUCTION
7.10.2. GENEA PRODUCT PORTFOLIO
7.10.3. GENEA RECENT ACTIVITIES
7.11. GLAXOSMITHKLINE PLC
7.11.1. INTRODUCTION
7.11.2. GLAXOSMITHKLINE PLC PRODUCT PORTFOLIO
7.11.3. GLAXOSMITHKLINE PLC RECENT ACTIVITIES
7.12. HALOTECH DNA
7.12.1. INTRODUCTION
7.12.2. HALOTECH DNA PRODUCT PORTFOLIO
7.12.3. HALOTECH DNA RECENT ACTIVITIES
7.13. IRVINE SCIENTIFIC
7.13.1. INTRODUCTION
7.13.2. IRVINE SCIENTIFIC PRODUCT PORTFOLIO
7.13.3. IRVINE SCIENTIFIC RECENT ACTIVITIES
7.14. JANSSEN PHARMACEUTICAL
7.14.1. INTRODUCTION
7.14.2. JANSSEN PHARMACEUTICAL PRODUCT PORTFOLIO
7.14.3. JANSSEN PHARMACEUTICAL RECENT ACTIVITIES
7.15. MERCK SERONO
7.15.1. INTRODUCTION
7.15.2. MERCK SERONO PRODUCT PORTFOLIO
7.15.3. MERCK SERONO RECENT ACTIVITIES
7.16. NOVARTIS INTERNATIONAL AG
7.16.1. INTRODUCTION
7.16.2. NOVARTIS INTERNATIONAL AG PRODUCT PORTFOLIO
7.16.3. NOVARTIS INTERNATIONAL AG RECENT ACTIVITIES
7.17. ORIGIO
7.17.1. INTRODUCTION
7.17.2. ORIGIO PRODUCT PORTFOLIO
7.17.3. ORIGIO RECENT ACTIVITIES
7.18. OVASCIENCE
7.18.1. INTRODUCTION
7.18.2. OVASCIENCE PRODUCT PORTFOLIO
7.18.3. OVASCIENCE RECENT ACTIVITIES
7.19. PFIZER INC.
7.19.1. INTRODUCTION
7.19.2. PFIZER INC. PRODUCT PORTFOLIO
7.19.3. PFIZER INC. RECENT ACTIVITIES
7.20. PRINCETON BIOMEDITECH CORP.
7.20.1. INTRODUCTION
7.20.2. PRINCETON BIOMEDITECH CORP. PRODUCT PORTFOLIO
7.20.3. PRINCETON BIOMEDITECH CORP. RECENT ACTIVITIES
1.1. RESEARCH METHODS AND TOOLS
1.2. MARKET BREAKDOWN
1.2.1. BY SEGMENTS
1.2.2. BY GEOGRAPHY
1.2.3. BY STAKEHOLDERS
2. MARKET OVERVIEW AND INSIGHTS
2.1. DEFINITION
2.2. ANALYST INSIGHTS & CURRENT MARKET TRENDS
2.2.1. KEY FINDINGS
2.2.2. RECOMMENDATION
2.2.3. CONCLUSION
2.3. REGULATIONS
2.3.1. UNITED STATES
2.3.2. EUROPEAN UNION
2.3.3. CHINA
2.3.4. INDIA
2.3.5. REST OF THE WORLD
3. MARKET DETERMINANT
3.1. MOTIVATORS
3.1.1. CHANGING LIFE STYLE
3.1.2. RISING TREND OF SURROGACY
3.1.3. INCREASING FEMALE GERIATRIC POPULATION
3.1.4. NEW TECHNOLOGIES TO AVOID MULTIPLE EMBRYO IMPLANTS
3.1.5. INCREASING IVF TREAMENT MARKET
3.1.6. GROWING INFERTILITY RATE AMONG FEMALE
3.2. RESTRAINTS
3.2.1. HIGH COST OF TREATMENT
3.2.2. INCREASING INCIDENCES OF TREATMENT FAILURES
3.2.3. SOCIAL STIGMA RELATED TO INFERTILITY TREATMENT
3.3. OPPORTUNITIES
3.3.1. INCREASING MEDICAL TOURISM
3.3.2. INCREASING AWARENESS AMONG PEOPLE
4. MARKET SEGMENTATION
4.1. GLOBAL FEMALE INFERTILITY MARKET BY DIAGNOSIS
4.1.1. OVULATION TESTING MARKET
4.1.2. HYSTEROSALPINGOGRAPHY MARKET
4.1.3. HYSTEROSCOPY MARKET
4.1.4. IMAGING TESTING MARKET
4.1.5. OVARIAN RESERVE TESTING MARKET
4.1.6. HORMONAL LEVEL TESTING MARKET
4.1.7. GENETIC TESTING MARKET
4.1.8. OTHERS
4.2. GLOBAL FEMALE INFERTILITY MARKET BY TREATMENT
4.2.1. DRUGS AND MEDICINE MARKET
4.2.2. SURGICAL MARKET
4.2.3. INTRAUTERINE INSEMINATION (IUI) MARKET
4.2.4. ASSISTED REPRODUCTIVE TECHNOLOGY (ART) MARKET
4.2.5. Others
5. COMPETITIVE LANDSCAPE
5.1. KEY STRATEGIES ANALYSIS
5.2. KEY COMPANY ANALYSIS
6. REGIONAL ANALYSIS
6.1. NORTH AMERICA
6.1.1. UNITED STATES
6.1.2. CANADA
6.1.3. REST OF NORTH AMERICA
6.2. EUROPE
6.2.1. UNITED KINGDOM
6.2.2. FRANCE
6.2.3. GERMANY
6.2.4. ITALY
6.2.5. SPAIN
6.2.6. REST OF EUROPE
6.3. ASIA PACIFIC
6.3.1. INDIA
6.3.2. CHINA
6.3.3. JAPAN
6.4. REST OF THE WORLD
7. COMPANY PROFILES
7.1. BAYER AG
7.1.1. Introduction
7.1.2. BAYER AG PRODUCT PORTFOLIO
7.1.3. BAYER AG RECENT ACTIVITIES
7.2. BRISTOL-MYERS SQUIBB CO.
7.2.1. INTRODUCTION
7.2.2. BRISTOL-MYERS SQUIBB CO. PRODUCT PORTFOLIO
7.2.3. BRISTOL-MYERS SQUIBB CO. RECENT ACTIVITIES
7.3. CHURCH & DWIGHT COMPANY INC.
7.3.1. INTRODUCTION
7.3.2. CHURCH & DWIGHT COMPANY INC. PRODUCT PORTFOLIO
7.3.3. CHURCH & DWIGHT COMPANY INC. RECENT ACTIVITIES
7.4. COOK MEDICAL, INC.
7.4.1. INTRODUCTION
7.4.2. COOK MEDICAL, INC. PRODUCT PORTFOLIO
7.4.3. COOK MEDICAL, INC. RECENT ACTIVITIES
7.5. COOPERSURGICAL INC.
7.5.1. INTRODUCTION
7.5.2. COOPERSURGICAL INC. PRODUCT PORTFOLIO
7.5.3. COOPERSURGICAL INC. RECENT ACTIVITIES
7.6. ELI LILLY & CO.
7.6.1. INTRODUCTION
7.6.2. ELI LILLY & CO. PRODUCT PORTFOLIO
7.6.3. ELI LILLY & CO. RECENT ACTIVITIES
7.7. EMD SERONO, INC
7.7.1. INTRODUCTION
7.7.2. EMD SERONO, INC PRODUCT PORTFOLIO
7.7.3. EMD SERONO, INC RECENT ACTIVITIES
7.8. ENDO PHARMACEUTICALS INC.
7.8.1. INTRODUCTION
7.8.2. ENDO PHARMACEUTICALS INC. PRODUCT PORTFOLIO
7.8.3. ENDO PHARMACEUTICALS INC. RECENT ACTIVITIES
7.9. FERRING PHARMACEUTICALS
7.9.1. INTRODUCTION
7.9.2. FERRING PHARMACEUTICALS PRODUCT PORTFOLIO
7.9.3. FERRING PHARMACEUTICALS RECENT ACTIVITIES
7.10. GENEA
7.10.1. INTRODUCTION
7.10.2. GENEA PRODUCT PORTFOLIO
7.10.3. GENEA RECENT ACTIVITIES
7.11. GLAXOSMITHKLINE PLC
7.11.1. INTRODUCTION
7.11.2. GLAXOSMITHKLINE PLC PRODUCT PORTFOLIO
7.11.3. GLAXOSMITHKLINE PLC RECENT ACTIVITIES
7.12. HALOTECH DNA
7.12.1. INTRODUCTION
7.12.2. HALOTECH DNA PRODUCT PORTFOLIO
7.12.3. HALOTECH DNA RECENT ACTIVITIES
7.13. IRVINE SCIENTIFIC
7.13.1. INTRODUCTION
7.13.2. IRVINE SCIENTIFIC PRODUCT PORTFOLIO
7.13.3. IRVINE SCIENTIFIC RECENT ACTIVITIES
7.14. JANSSEN PHARMACEUTICAL
7.14.1. INTRODUCTION
7.14.2. JANSSEN PHARMACEUTICAL PRODUCT PORTFOLIO
7.14.3. JANSSEN PHARMACEUTICAL RECENT ACTIVITIES
7.15. MERCK SERONO
7.15.1. INTRODUCTION
7.15.2. MERCK SERONO PRODUCT PORTFOLIO
7.15.3. MERCK SERONO RECENT ACTIVITIES
7.16. NOVARTIS INTERNATIONAL AG
7.16.1. INTRODUCTION
7.16.2. NOVARTIS INTERNATIONAL AG PRODUCT PORTFOLIO
7.16.3. NOVARTIS INTERNATIONAL AG RECENT ACTIVITIES
7.17. ORIGIO
7.17.1. INTRODUCTION
7.17.2. ORIGIO PRODUCT PORTFOLIO
7.17.3. ORIGIO RECENT ACTIVITIES
7.18. OVASCIENCE
7.18.1. INTRODUCTION
7.18.2. OVASCIENCE PRODUCT PORTFOLIO
7.18.3. OVASCIENCE RECENT ACTIVITIES
7.19. PFIZER INC.
7.19.1. INTRODUCTION
7.19.2. PFIZER INC. PRODUCT PORTFOLIO
7.19.3. PFIZER INC. RECENT ACTIVITIES
7.20. PRINCETON BIOMEDITECH CORP.
7.20.1. INTRODUCTION
7.20.2. PRINCETON BIOMEDITECH CORP. PRODUCT PORTFOLIO
7.20.3. PRINCETON BIOMEDITECH CORP. RECENT ACTIVITIES
LIST OF TABLES
TABLE #1 GLOBAL FEMALE INFERTILITY DIAGNOSIS AND TREATMENT market RESEARCH AND ANALYSIS, BY DIAGNOSIS 2015-2022 ($ MILLION)
TABLE #2 GLOBAL OVULATION TESTING MARKET RESEARCH AND ANALYSIS, 2015-2022 ($ MILLION)
TABLE #3 GLOBAL HYSTEROSALPINGOGRAPHY MARKET RESEARCH AND ANALYSIS, 2015-2022 ($ MILLION)
TABLE #4 GLOBAL HYSTERSCOPY MARKET RESEARCH AND ANALYSIS, 2015-2022 ($ MILLION)
TABLE #5 GLOBAL IMAGING TESTING MARKET RESEARCH AND ANALYSIS, 2015-2022 ($ MILLION)
TABLE #6 GLOBAL OVARIAN RESERVE TESTING MARKET RESEARCH AND ANALYSIS, 2015-2022 ($ MILLION)
TABLE #7 GLOBAL OVARIAN RESERVE TESTING MARKET RESEARCH AND ANALYSIS, 2015-2022 ($ MILLION)
TABLE #8 GLOBAL HARMONALLEVEL TESTING MARKET RESEARCH AND ANALYSIS, 2015-2022 ($ MILLION)
TABLE #9 GLOBAL GENETIC TESTING MARKET RESEARCH AND ANALYSIS, 2015-2022 ($ MILLION)
TABLE #10 GLOBAL OTHERS MARKET RESEARCH AND ANALYSIS, 2015-2022 ($ MILLION)
TABLE #11 GLOBAL FEMALE INFERTILITY DIAGNOSIS AND TREATMENT market RESEARCH AND ANALYSIS, BY TREATMENT 2015-2022 ($ MILLION)
TABLE #12 GLOBAL DRUG & MEDICINES MARKET RESEARCH AND ANALYSIS, 2015-2022 ($ MILLION)
TABLE #13 GLOBAL SURGICAL MARKET RESEARCH AND ANALYSIS, BY CONNECTOR, 2015-2022 ($ MILLION)
TABLE #14 GLOBAL INTRAUTERINE INSEMINATION(iui) MARKET RESEARCH AND ANALYSIS, 2015-2022 ($ MILLION)
TABLE #15 GLOBAL ASSISTED REPRODUCTIVE TECHNOLOGY MARKET RESEARCH AND ANALYSIS, 2015-2022 ($ MILLION)
TABLE #16 GLOBAL OTHERS MARKET RESEARCH AND ANALYSIS, 2015-2022 ($ MILLION)
TABLE #46 BAYER AG PRODUCT PORTFOLIO
TABLE #47 BAYER AG RECENT ACTIVITIES
TABLE #48 BRISTOL-MYERS SQUIBB CO. PRODUCT PORTFOLIO
TABLE #49 BRISTOL-MYERS SQUIBB CO. RECENT ACTIVITIES
TABLE #50 CHURCH & DWIGHT COMPANY INC. PRODUCT PORTFOLIO
TABLE #51 CHURCH & DWIGHT COMPANY INC. RECENT ACTIVITIES
TABLE #52 COOK MEDICAL, INC. PRODUCT PORTFOLIO
TABLE #53 COOK MEDICAL, INC. RECENT ACTIVITIES
TABLE #54 COOPERSURGICAL INC. PRODUCT PORTFOLIO
TABLE #55 COOPERSURGICAL INC. RECENT ACTIVITIES
TABLE #56 ELI LILLY & CO. PRODUCT PORTFOLIO
TABLE #57 ELI LILLY & CO. RECENT ACTIVITIES
TABLE #58 EMD SERONO, INC PRODUCT PORTFOLIO
TABLE #59 EMD SERONO, INC RECENT ACTIVITIES
TABLE #60 ENDO PHARMACEUTICALS INC. PRODUCT PORTFOLIO
TABLE #61 ENDO PHARMACEUTICALS INC. RECENT ACTIVITIES
TABLE #62 FERRING PHARMACEUTICALS PRODUCT PORTFOLIO
TABLE #63 FERRING PHARMACEUTICALS RECENT ACTIVITIES
TABLE #64 GENEA PRODUCT PORTFOLIO
TABLE #65 GENEA RECENT ACTIVITIES
TABLE #66 GLAXOSMITHKLINE PLC PRODUCT PORTFOLIO
TABLE #67 GLAXOSMITHKLINE PLC RECENT ACTIVITIES
TABLE #68 HALOTECH DNA PRODUCT PORTFOLIO
TABLE #69 HALOTECH DNA RECENT ACTIVITIES
TABLE #70 IRVINE SCIENTIFIC PRODUCT PORTFOLIO
TABLE #71 IRVINE SCIENTIFIC RECENT ACTIVITIES
TABLE #72 JANSSEN PHARMACEUTICAL PRODUCT PORTFOLIO
TABLE #73 JANSSEN PHARMACEUTICAL RECENT ACTIVITIES
TABLE #74 MERCK SERONO PRODUCT PORTFOLIO
TABLE #75 MERCK SERONO RECENT ACTIVITIES
TABLE #76 NOVARTIS INTERNATIONAL AG PRODUCT PORTFOLIO
TABLE #77 NOVARTIS INTERNATIONAL AG RECENT ACTIVITIES
TABLE #78 ORIGIO PRODUCT PORTFOLIO
TABLE #79 ORIGIO RECENT ACTIVITIES
TABLE #80 OVASCIENCE PRODUCT PORTFOLIO
TABLE #81 OVASCIENCE RECENT ACTIVITIES
TABLE #82 PFIZER INC. PRODUCT PORTFOLIO
TABLE #83 PFIZER INC. RECENT ACTIVITIES
TABLE #84 PRINCETON BIOMEDITECH CORP. PRODUCT PORTFOLIO
TABLE #85 PRINCETON BIOMEDITECH CORP. RECENT ACTIVITIES
TABLE #1 GLOBAL FEMALE INFERTILITY DIAGNOSIS AND TREATMENT market RESEARCH AND ANALYSIS, BY DIAGNOSIS 2015-2022 ($ MILLION)
TABLE #2 GLOBAL OVULATION TESTING MARKET RESEARCH AND ANALYSIS, 2015-2022 ($ MILLION)
TABLE #3 GLOBAL HYSTEROSALPINGOGRAPHY MARKET RESEARCH AND ANALYSIS, 2015-2022 ($ MILLION)
TABLE #4 GLOBAL HYSTERSCOPY MARKET RESEARCH AND ANALYSIS, 2015-2022 ($ MILLION)
TABLE #5 GLOBAL IMAGING TESTING MARKET RESEARCH AND ANALYSIS, 2015-2022 ($ MILLION)
TABLE #6 GLOBAL OVARIAN RESERVE TESTING MARKET RESEARCH AND ANALYSIS, 2015-2022 ($ MILLION)
TABLE #7 GLOBAL OVARIAN RESERVE TESTING MARKET RESEARCH AND ANALYSIS, 2015-2022 ($ MILLION)
TABLE #8 GLOBAL HARMONALLEVEL TESTING MARKET RESEARCH AND ANALYSIS, 2015-2022 ($ MILLION)
TABLE #9 GLOBAL GENETIC TESTING MARKET RESEARCH AND ANALYSIS, 2015-2022 ($ MILLION)
TABLE #10 GLOBAL OTHERS MARKET RESEARCH AND ANALYSIS, 2015-2022 ($ MILLION)
TABLE #11 GLOBAL FEMALE INFERTILITY DIAGNOSIS AND TREATMENT market RESEARCH AND ANALYSIS, BY TREATMENT 2015-2022 ($ MILLION)
TABLE #12 GLOBAL DRUG & MEDICINES MARKET RESEARCH AND ANALYSIS, 2015-2022 ($ MILLION)
TABLE #13 GLOBAL SURGICAL MARKET RESEARCH AND ANALYSIS, BY CONNECTOR, 2015-2022 ($ MILLION)
TABLE #14 GLOBAL INTRAUTERINE INSEMINATION(iui) MARKET RESEARCH AND ANALYSIS, 2015-2022 ($ MILLION)
TABLE #15 GLOBAL ASSISTED REPRODUCTIVE TECHNOLOGY MARKET RESEARCH AND ANALYSIS, 2015-2022 ($ MILLION)
TABLE #16 GLOBAL OTHERS MARKET RESEARCH AND ANALYSIS, 2015-2022 ($ MILLION)
TABLE #46 BAYER AG PRODUCT PORTFOLIO
TABLE #47 BAYER AG RECENT ACTIVITIES
TABLE #48 BRISTOL-MYERS SQUIBB CO. PRODUCT PORTFOLIO
TABLE #49 BRISTOL-MYERS SQUIBB CO. RECENT ACTIVITIES
TABLE #50 CHURCH & DWIGHT COMPANY INC. PRODUCT PORTFOLIO
TABLE #51 CHURCH & DWIGHT COMPANY INC. RECENT ACTIVITIES
TABLE #52 COOK MEDICAL, INC. PRODUCT PORTFOLIO
TABLE #53 COOK MEDICAL, INC. RECENT ACTIVITIES
TABLE #54 COOPERSURGICAL INC. PRODUCT PORTFOLIO
TABLE #55 COOPERSURGICAL INC. RECENT ACTIVITIES
TABLE #56 ELI LILLY & CO. PRODUCT PORTFOLIO
TABLE #57 ELI LILLY & CO. RECENT ACTIVITIES
TABLE #58 EMD SERONO, INC PRODUCT PORTFOLIO
TABLE #59 EMD SERONO, INC RECENT ACTIVITIES
TABLE #60 ENDO PHARMACEUTICALS INC. PRODUCT PORTFOLIO
TABLE #61 ENDO PHARMACEUTICALS INC. RECENT ACTIVITIES
TABLE #62 FERRING PHARMACEUTICALS PRODUCT PORTFOLIO
TABLE #63 FERRING PHARMACEUTICALS RECENT ACTIVITIES
TABLE #64 GENEA PRODUCT PORTFOLIO
TABLE #65 GENEA RECENT ACTIVITIES
TABLE #66 GLAXOSMITHKLINE PLC PRODUCT PORTFOLIO
TABLE #67 GLAXOSMITHKLINE PLC RECENT ACTIVITIES
TABLE #68 HALOTECH DNA PRODUCT PORTFOLIO
TABLE #69 HALOTECH DNA RECENT ACTIVITIES
TABLE #70 IRVINE SCIENTIFIC PRODUCT PORTFOLIO
TABLE #71 IRVINE SCIENTIFIC RECENT ACTIVITIES
TABLE #72 JANSSEN PHARMACEUTICAL PRODUCT PORTFOLIO
TABLE #73 JANSSEN PHARMACEUTICAL RECENT ACTIVITIES
TABLE #74 MERCK SERONO PRODUCT PORTFOLIO
TABLE #75 MERCK SERONO RECENT ACTIVITIES
TABLE #76 NOVARTIS INTERNATIONAL AG PRODUCT PORTFOLIO
TABLE #77 NOVARTIS INTERNATIONAL AG RECENT ACTIVITIES
TABLE #78 ORIGIO PRODUCT PORTFOLIO
TABLE #79 ORIGIO RECENT ACTIVITIES
TABLE #80 OVASCIENCE PRODUCT PORTFOLIO
TABLE #81 OVASCIENCE RECENT ACTIVITIES
TABLE #82 PFIZER INC. PRODUCT PORTFOLIO
TABLE #83 PFIZER INC. RECENT ACTIVITIES
TABLE #84 PRINCETON BIOMEDITECH CORP. PRODUCT PORTFOLIO
TABLE #85 PRINCETON BIOMEDITECH CORP. RECENT ACTIVITIES
LIST OF FIGURES
FIGURE #1 NORTH AMERICA MARKET RESEARCH AND ANALYSIS, 2015-2022
FIGURE #2 US MARKET RESEARCH AND ANALYSIS, 2015-2022
FIGURE #3 CANADA MARKET RESEARCH AND ANALYSIS, 2015-2022
FIGURE #4 EUROPEAN MARKET RESEARCH AND ANALYSIS, 2015-2022
FIGURE #5 UK MARKET RESEARCH AND ANALYSIS, 2015-2022
FIGURE #6 FRANCE MARKET RESEARCH AND ANALYSIS, 2015-2022
FIGURE #7 GERMANY MARKET RESEARCH AND ANALYSIS, 2015-2022
FIGURE #8 ITALY MARKET RESEARCH AND ANALYSIS, 2015-2022
FIGURE #9 SPAIN MARKET RESEARCH AND ANALYSIS, 2015-2022
FIGURE #10 ROE MARKET RESEARCH AND ANALYSIS, 2015-2022
FIGURE #11 ASIA PACIFIC MARKET RESEARCH AND ANALYSIS, 2015-2022
FIGURE #12 INDIA MARKET RESEARCH AND ANALYSIS, 2015-2022
FIGURE #13 CHINA MARKET RESEARCH AND ANALYSIS, 2015-2022
FIGURE #14 JAPAN MARKET RESEARCH AND ANALYSIS, 2015-2022
FIGURE #15 ROPAC MARKET RESEARCH AND ANALYSIS, 2015-2022
FIGURE #16 REST OF THE WORLD MARKET RESEARCH AND ANALYSIS, 2015-2022
COMPANIES MENTIONED
1. Bayer AG
2. Bristol-Mayer Squibb co.
3. Church & Dwight co.
4. Cook medical inc.
5. Coopersurgical inc.
6. Eli-lilly & co.
7. EMD serono inc.
8. ENDO pharamceuticals
9. Ferring pharmaceuticals
10. Genea
11. Glaxosmithkline
12. Halotech DNA
13. Irvine Scientific
14. Janssen Pharmaceuticals
15. Merck Serono
16. Novartis International AG
17. Origio
18. Ovascience
19. Pfizer inc.
20. Princeton biomeditech
FIGURE #1 NORTH AMERICA MARKET RESEARCH AND ANALYSIS, 2015-2022
FIGURE #2 US MARKET RESEARCH AND ANALYSIS, 2015-2022
FIGURE #3 CANADA MARKET RESEARCH AND ANALYSIS, 2015-2022
FIGURE #4 EUROPEAN MARKET RESEARCH AND ANALYSIS, 2015-2022
FIGURE #5 UK MARKET RESEARCH AND ANALYSIS, 2015-2022
FIGURE #6 FRANCE MARKET RESEARCH AND ANALYSIS, 2015-2022
FIGURE #7 GERMANY MARKET RESEARCH AND ANALYSIS, 2015-2022
FIGURE #8 ITALY MARKET RESEARCH AND ANALYSIS, 2015-2022
FIGURE #9 SPAIN MARKET RESEARCH AND ANALYSIS, 2015-2022
FIGURE #10 ROE MARKET RESEARCH AND ANALYSIS, 2015-2022
FIGURE #11 ASIA PACIFIC MARKET RESEARCH AND ANALYSIS, 2015-2022
FIGURE #12 INDIA MARKET RESEARCH AND ANALYSIS, 2015-2022
FIGURE #13 CHINA MARKET RESEARCH AND ANALYSIS, 2015-2022
FIGURE #14 JAPAN MARKET RESEARCH AND ANALYSIS, 2015-2022
FIGURE #15 ROPAC MARKET RESEARCH AND ANALYSIS, 2015-2022
FIGURE #16 REST OF THE WORLD MARKET RESEARCH AND ANALYSIS, 2015-2022
COMPANIES MENTIONED
1. Bayer AG
2. Bristol-Mayer Squibb co.
3. Church & Dwight co.
4. Cook medical inc.
5. Coopersurgical inc.
6. Eli-lilly & co.
7. EMD serono inc.
8. ENDO pharamceuticals
9. Ferring pharmaceuticals
10. Genea
11. Glaxosmithkline
12. Halotech DNA
13. Irvine Scientific
14. Janssen Pharmaceuticals
15. Merck Serono
16. Novartis International AG
17. Origio
18. Ovascience
19. Pfizer inc.
20. Princeton biomeditech
